Recently, our colleagues at Minneapolis Heart Institute and Abbott Northwestern Hospital have published a case report on the use of Hemolung RAS to treat a COVID-19 patient.

“Treatment of Severe Hypercapnic Respiratory Failure Caused by SARS-CoV-2 Lung Injury with ECCO2R Using the Hemolung Respiratory Assist System”

Click here to access the user report.


ALung hosted a webinar on the use of Hemolung RAS to treat COVID-19 patients.  Four physicians review COVID-19 patient cases and present their findings.

“The Role of ECCO2R in COVID-19 with Real World Physician Experience”.

Click here to watch the video of the webinar.

The first fully integrated respiratory dialysis system.


ECCO₂R therapy with the Hemolung RAS allows carbon dioxide to be removed from the blood independently of the lungs with the aim of facilitating the avoidance or reduction of intubation and invasive mechanical ventilation.

The first fully-integrated Respiratory Dialysis system, the Hemolung RAS combines advanced technology with user-centered design to provide simple, effective, and minimally invasive extracorporeal CO2 removal (ECCO2R).

Removing carbon dioxide and delivering oxygen directly to the blood allows the patient’s lungs to rest and heal while avoiding intubation and/or facilitating protective ventilation.

2014 – ALung treats first US Patient in emergency use.

ALung’s Hemolung RAS is currently undergoing an FDA PMA trial for clearance in the US (VENT-AVOID Trial).

ECCO2R removes excess carbon dioxide directly from a patient's bloodstream.
The first fully-integrated Respiratory Dialysis® system
Resources for using the Hemolung RAS.